STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial nerve palsies, according to early results from a Phase 3 clinical trial reported Tuesday. 

While still preliminary, the benign neurotoxicity assessment for the therapy, called anito-cel, suggests it could be a safer option for patients with multiple myeloma compared to Carvytki, a currently approved CAR-T treatment from Johnson & Johnson and Legend Biotech.

Parkinsonian symptoms and cranial nerve palsies have been reported in approximately 10% of patients treated with Carvykti, according to published clinical trial results. 

Continue to STAT+ to read the full story…